These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

858 related items for PubMed ID: 17261671

  • 21. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B, Staels B.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [Abstract] [Full Text] [Related]

  • 22. Peroxisome proliferator-activated receptors and inflammation.
    Moraes LA, Piqueras L, Bishop-Bailey D.
    Pharmacol Ther; 2006 Jun; 110(3):371-85. PubMed ID: 16168490
    [Abstract] [Full Text] [Related]

  • 23. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M.
    Prog Mol Biol Transl Sci; 2014 Jun; 121():217-66. PubMed ID: 24373239
    [Abstract] [Full Text] [Related]

  • 24. [Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy].
    Bełtowski J, Wójcicka G, Jamroz A.
    Postepy Hig Med Dosw; 2003 Jun; 57(2):199-217. PubMed ID: 12866356
    [Abstract] [Full Text] [Related]

  • 25. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA.
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
    [Abstract] [Full Text] [Related]

  • 26. Peroxisome proliferator-activated receptors and the metabolic syndrome.
    Bragt MC, Popeijus HE.
    Physiol Behav; 2008 May 23; 94(2):187-97. PubMed ID: 18191967
    [Abstract] [Full Text] [Related]

  • 27. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
    Alemán G, Torres N, Tovar AR.
    Rev Invest Clin; 2004 May 23; 56(3):351-67. PubMed ID: 15612519
    [Abstract] [Full Text] [Related]

  • 28. [Nuclear receptors PPAR as a drug target in metabolic disorders].
    Stolarczyk M, Gutman W, Derlacz RA.
    Postepy Biochem; 2011 May 23; 57(2):207-14. PubMed ID: 21913422
    [Abstract] [Full Text] [Related]

  • 29. The human semaphorin 6B gene is down regulated by PPARs.
    Collet P, Domenjoud L, Devignes MD, Murad H, Schohn H, Dauça M.
    Genomics; 2004 Jun 23; 83(6):1141-50. PubMed ID: 15177567
    [Abstract] [Full Text] [Related]

  • 30. Peroxisome proliferator-activated receptors: Targets for the treatment of metabolic illnesses (Review).
    Moore-Carrasco R, Poblete Bustamante M, González Guerra O, Leiva Madariaga E, Mujica Escudero V, Aranguez Arellano C, Palomo I.
    Mol Med Rep; 2008 Jun 23; 1(3):317-24. PubMed ID: 21479412
    [Abstract] [Full Text] [Related]

  • 31. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling.
    Gardner OS, Dewar BJ, Graves LM.
    Mol Pharmacol; 2005 Oct 23; 68(4):933-41. PubMed ID: 16020742
    [Abstract] [Full Text] [Related]

  • 32. Characterization of Madin-Darby bovine kidney cell line for peroxisome proliferator-activated receptors: temporal response and sensitivity to fatty acids.
    Bionaz M, Baumrucker CR, Shirk E, Vanden Heuvel JP, Block E, Varga GA.
    J Dairy Sci; 2008 Jul 23; 91(7):2808-13. PubMed ID: 18565938
    [Abstract] [Full Text] [Related]

  • 33. Nuclear receptors of the peroxisome proliferator-activated receptor (PPAR) family in gestational diabetes: from animal models to clinical trials.
    Arck P, Toth B, Pestka A, Jeschke U.
    Biol Reprod; 2010 Aug 01; 83(2):168-76. PubMed ID: 20427759
    [Abstract] [Full Text] [Related]

  • 34. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus.
    Rosenson RS.
    Am J Cardiol; 2007 Feb 19; 99(4A):96B-104B. PubMed ID: 17307062
    [Abstract] [Full Text] [Related]

  • 35. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
    Chinetti-Gbaguidi G, Fruchart JC, Staels B.
    Biomarkers; 2005 Nov 19; 10 Suppl 1():S30-6. PubMed ID: 16298909
    [Abstract] [Full Text] [Related]

  • 36. Peroxisome proliferator-activated receptors and their relevance to dermatology.
    Friedmann PS, Cooper HL, Healy E.
    Acta Derm Venereol; 2005 Nov 19; 85(3):194-202. PubMed ID: 16040401
    [Abstract] [Full Text] [Related]

  • 37. An overview on biological mechanisms of PPARs.
    Kota BP, Huang TH, Roufogalis BD.
    Pharmacol Res; 2005 Feb 19; 51(2):85-94. PubMed ID: 15629253
    [Abstract] [Full Text] [Related]

  • 38. Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
    Chinetti-Gbaguidi G, Staels B.
    Pharmacogenomics; 2007 Nov 19; 8(11):1567-80. PubMed ID: 18034622
    [Abstract] [Full Text] [Related]

  • 39. PPAR alpha, fibrates, lipid metabolism and inflammation.
    Duval C, Fruchart JC, Staels B.
    Arch Mal Coeur Vaiss; 2004 Jun 19; 97(6):665-72. PubMed ID: 15283041
    [Abstract] [Full Text] [Related]

  • 40. Peroxisome proliferator-activated receptors and retinoid X receptor-alpha in term human gestational tissues: tissue specific and labour-associated changes.
    Holdsworth-Carson SJ, Permezel M, Riley C, Rice GE, Lappas M.
    Placenta; 2009 Feb 19; 30(2):176-86. PubMed ID: 19070893
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.